Recalled Medicines & supplements – Current GIS Alerts 2026
Found 700 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
BDS N
Out-of-specification results were found in archival samples regarding the parameter "content of budesonide-related substances", due to exceeded impurity levels. Potential effects: possible adverse reactions, toxicity, or lack of expected therapeutic efficacy.
CLOPIDOGREL GENOPTIM
An incorrect name of the active substance was placed on the unit packaging, which may lead to medication errors and use of an inappropriate medicine or dose. Potential effects: lack of treatment efficacy, therapy complications, possible serious adverse reactions.
BUDIXON NEB
Exceedance of the specification limit for the content of budesonide related substances was found in one batch and there is a probability of exceeding this limit in other batches of the product. Potential effects: possible lack of efficacy, unpredictable drug action, therapy complications.
BUDIXON NEB
Exceedance of the specification limit for the content of budesonide-related substances was found for one batch and a probability of exceeding this limit for other batches of the product. Potential effects: lack of treatment efficacy or unpredictable adverse reactions.
BUDIXON NEB
Exceeding of specification limits for the content of budesonide related substances was found for batch 060218, with a probability of exceeding the limit for other batches still within shelf-life. Potential effects: lack of treatment efficacy, unpredictable adverse reactions.
BUDIXON NEB
Exceeding the specification limit for the parameter of budesonide-related substances was found for batch 060218 and a probability of exceeding the limit for other in-date batches. Potential effects: lack of treatment efficacy or unpredictable adverse reactions.
PŁYN BUROWA
Out-of-specification results were found in the ongoing stability program for parameters: appearance and purity — sulfate content, meaning the medicinal product does not meet established quality requirements. Potential effects: lack of therapeutic efficacy or unforeseen adverse reactions.
POLYVACCINUM MITE
In one bottle of the medicinal product batch a solid body floating on the surface of the suspension was found, which poses a potential risk to patients' health. Potential effects: complications after administration, irritation, inflammatory reaction, lack of therapeutic efficacy.
BDS N
Out-of-specification results were found for the content of related substances of budesonide, due to exceeded impurity levels. Potential effects: lack of treatment efficacy or adverse reactions caused by impurities.
ROZAPROST MONO
No information in the text about the type of hazard, contamination, quality defect or safety issue concerning a specific medicinal product or batch. Potential effects: impossible to assess risk, need to exercise caution until full data are obtained.
ROZAPROST MONO
No information in the text about any specific hazard to the quality, safety, or efficacy of any medicinal product. Potential effects: no effects can be determined based on the available information.
BENODIL
Risk of not meeting finished product specification with respect to the parameter of related substances content, which may indicate a quality defect of the medicinal product. Potential effects: lack of efficacy or unpredictable adverse reactions.
BENODIL
A risk was identified that the finished product may not meet specification requirements regarding the level of related substances, indicating a possible quality defect. Potential effects: possible lack of efficacy or unpredictable adverse reactions.
BUDIXON NEB
Exceeding the specification limit for the parameter of budesonide-related substances content was found, meaning the product does not meet established quality requirements. Potential effects: possible lack of treatment efficacy or adverse reactions.
BDS N
It was confirmed that the specification limit for the parameter 'content of related substances' was exceeded, due to an increased level of impurities. Potential effects: possible adverse reactions, toxicity, lack of therapeutic efficacy.
BDS N
The specification limit for the parameter "content of related substances" was exceeded due to increased impurity content, constituting a quality defect of the medicinal product and a potential risk to patients' health. Potential effects: poisoning, adverse reactions, lack of therapeutic efficacy.
ASANIX
A quality defect was found: in the ongoing stability testing program an out-of-specification result was obtained for the parameter of active substance release from the tablet, meaning the drug may not release the correct amount of active ingredient. Potential effects: lack of treatment efficacy or unpredictable drug action.
BENODIL
It was found that the specification limit for the related substances content parameter was exceeded, meaning the product does not meet established quality requirements. Potential effects: possible lack of efficacy, unpredictable adverse reactions.
3% ROZTWÓR KWASU BOROWEGO
A quality defect was found: boric acid content is 0.3% instead of 2.8%-3.2% and the form is non-compliant, which may lead to compounded medicines with incorrect strength and efficacy. Potential effects: lack of therapeutic efficacy, possible disease complications.
3% ROZTWÓR KWASU BOROWEGO
A quality defect was found: too low boric acid content (should be 2.8%–3.2%, actual 0.3%) and non‑compliant form, which may lead to preparation of compounded medicines with incorrect strength and effectiveness. Potential effects: lack of drug efficacy, risk of therapy complications.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.